Drug Trial Radar · NCT01732757
A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis
Last checked: Nov 20, 2026Latest source record: Jan 14, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
157
Actual
Start
Nov 2012
Primary completion
Dec 2012
Study completion Dec 2012
Sponsor
- Lead sponsor
- AllerganAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Nov 26, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 10 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy of Lastacaft® (Alcaftadine 0.25%) and Pataday™ (Olopatadine 0.2%) as compared to each other and to placebo in the prevention of ocular itching associated with allergic conjunctivitis.
Conditions
- Conjunctivitis, Allergic
Interventions
Alcaftadine 0.25%Drug
One drop of Lastacaft® (Alcaftadine 0.25%) administered in both eyes on Day 0.
Olopatadine 0.2%Drug
One drop of Pataday™ (Olopatadine 0.2%) administered in both eyes on Day 0.
dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%Drug
One drop of placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) administered in both eyes on Day 0.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ocular Itching Evaluated by the Subject 3 Minutes Post Challenge on Day 0Time frame: Day 0 at 3 Minutes Post Challenge
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Memphis, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.